Patents by Inventor Mark Erlander

Mark Erlander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7179604
    Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: February 20, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
  • Publication number: 20070020655
    Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Application
    Filed: June 2, 2006
    Publication date: January 25, 2007
    Applicant: AviaraDx, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma
  • Publication number: 20060286579
    Abstract: This invention provides gene sequence identities and methods for the determination of cellular gene expression and the comparison of expression levels between different gene sequences and between different cells. The gene sequences may be used as reference, normalization, or “housekeeping” gene sequences, the expression of which remains consistent in individual cells, even under different conditions, as well as among cells from different samples and origins.
    Type: Application
    Filed: June 2, 2006
    Publication date: December 21, 2006
    Applicant: AviaraDx, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma
  • Publication number: 20060263806
    Abstract: Methods and compositions are provided for the detection of breast cancer based upon the identification of three biomarkers for non-normal breast cells. The biomarkers were identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer. Two biomarkers display increased expression in non-normal cells while the third biomarker displays decreased expression in non-normal cells.
    Type: Application
    Filed: May 2, 2006
    Publication date: November 23, 2006
    Applicant: AviaraDx, Inc.
    Inventors: Xiao-Jun Ma, Dennis Sgroi, Mark Erlander
  • Publication number: 20060246434
    Abstract: A method of processing images includes the steps of retrieving a source image file including pixel date, creating a destination image file buffer, mapping the pixel data from the source image file to the destination image file buffer, and outputting pixel, data from the destination image file buffer as a destination image file. The step of mapping pixel data from the source image file to the destination image file buffer can include the step of interpolating the source image pixel data to produce pixel date for the destination image file buffer. Border pixel data can be added to the source image file to improve the efficiency interpolation step. The source image file can be a panoramic projection image file, and can include pixel data from a plurality of images. An apparatus for processing images in accordance with the method is also provided.
    Type: Application
    Filed: March 14, 2003
    Publication date: November 2, 2006
    Inventors: Mark Erlander, Ranelle Salunga, Theresa Taylor, Liang You, Steven Kunitake
  • Publication number: 20060234287
    Abstract: Methods and compositions for the identification of breast cancer progression signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages of breast cancer.
    Type: Application
    Filed: June 26, 2006
    Publication date: October 19, 2006
    Applicant: AviaraDx, Inc.
    Inventors: Mark Erlander, Xia-Jun Ma, Dennis Sgroi
  • Publication number: 20060154267
    Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.
    Type: Application
    Filed: March 24, 2005
    Publication date: July 13, 2006
    Applicant: Arcturus Bioscience, Inc.
    Inventors: Xiao-Jun Ma, Mark Erlander, Dennis Sgroi, Edward Enright
  • Patent number: 7049401
    Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: May 23, 2006
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
  • Publication number: 20060094035
    Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Application
    Filed: June 3, 2005
    Publication date: May 4, 2006
    Applicant: Arcturus Bioscience, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma
  • Publication number: 20060088851
    Abstract: This invention relates to the detection of increased expression from the HoxB13 (homeobox B13) gene as indicative of an invasive or metastatic cancer phenotype. The invention provides methods of detecting the level of expression from the HoxB13 gene, optionally in combination with nodal status, as an indicator of the invasive or metastatic phenotype as well as increased cellular migration and/or mobility. The invention also provides for the measurement of expression from the HoxB13 gene to assist in the determination of patient prognosis as well as clinical diagnosis and treatment.
    Type: Application
    Filed: June 3, 2005
    Publication date: April 27, 2006
    Applicants: Arcturus Bioscience, Inc., General Hospital Corporation
    Inventors: Mark Erlander, Dennis Sgroi, Xiao-Jun Ma
  • Publication number: 20060063170
    Abstract: This invention relates to the determination of RNA quality, or RNA integrity, in a biological sample. The extent of RNA degradation, or retention of RNA integrity, is determined based upon the comparison of the relative amount of two sequences of a representative RNA molecule in the sample. Compositions and methods related to the determination are provided to assess RNA quality.
    Type: Application
    Filed: March 18, 2005
    Publication date: March 23, 2006
    Applicant: Arcturus Bioscience, Inc.
    Inventors: Mark Erlander, Li Ding
  • Publication number: 20050255481
    Abstract: The invention relates to the identification and use of sequences from expressed progesterone receptor transcripts in relation to breast cancer. In particular, the invention provides the identities of polynucleotide sequences that may be used to identify populations that are positive for estrogen receptor expression. The expressed polynucleotide sequences may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient.
    Type: Application
    Filed: May 11, 2004
    Publication date: November 17, 2005
    Inventors: Xiao-Jun Ma, Edward Enright, Mark Erlander
  • Publication number: 20050239079
    Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
    Type: Application
    Filed: December 2, 2003
    Publication date: October 27, 2005
    Applicant: Arcturus Engineering, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma, Dennis Sgroi
  • Publication number: 20050239083
    Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 27, 2005
    Applicant: Arcturus Bioscience, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma, Dennis Sgroi
  • Publication number: 20050208500
    Abstract: The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of populations that are positive and negative for estrogen receptor expression. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient, including breast cancer survival.
    Type: Application
    Filed: March 4, 2004
    Publication date: September 22, 2005
    Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
  • Publication number: 20050164342
    Abstract: cDNA molecules coding for GAD65 polypeptide. The invention provides cDNA molecules comprising a part of the cDNA sequence of GAD65 which encode at least one epitope for autoantibodies to GAD65. The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD65. The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD65. In another embodiment, the invention provides for the detection of autoantibodies to GAD65 using the GAD65 polypeptides coded for by the cDNA molecules of the invention.
    Type: Application
    Filed: August 15, 2003
    Publication date: July 28, 2005
    Inventors: Allan Tobin, Mark Erlander, Daniel Kaufman
  • Publication number: 20050130194
    Abstract: The present invention provides methods for the amplification of nucleic acid molecules. Methods for amplifying target polynucleotides, including mRNA, using oligonucleotides, DNA and RNA polymerases are provided. The invention further provides compositions and kits for practicing the methods, as well as methods which use the amplification products.
    Type: Application
    Filed: September 15, 2004
    Publication date: June 16, 2005
    Applicant: Arcturus Bioscience, Inc.
    Inventors: Mark Erlander, Ranelle Salunga
  • Publication number: 20050124795
    Abstract: DNA encoding human 5-HT3-C has been cloned and characterized. The recombinant protein is capable of forming biologically active human 5-HT3-C protein. The cDNA has been expressed in recombinant host cells that produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Application
    Filed: September 12, 2003
    Publication date: June 9, 2005
    Inventors: Adrienne Dubin, Mark Erlander, Arne Huvar, Rene Huvar, Lukas Buehler
  • Publication number: 20050100933
    Abstract: The invention provides for the identification and use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the invention provides the identities of genes that are correlated with patient survival and breast cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with breast cancer and to predict breast cancer recurrence and. The profiles may also be used in the study and/or diagnosis of breast cancer cells and tissue, including the grading of invasive breast cancer, as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of breast cancer based upon the likelihood of life expectancy and recurrence.
    Type: Application
    Filed: June 18, 2004
    Publication date: May 12, 2005
    Applicant: Arcturus Bioscience, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
  • Publication number: 20050095607
    Abstract: The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast cancer patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast cancer survival.
    Type: Application
    Filed: March 5, 2004
    Publication date: May 5, 2005
    Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff